The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001##
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The present invention relates to a process for preparing antibody-drug conjugates and to antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.

The present invention relates to a process for preparing antibody-drug conjugates and to antibody-drug conjugates wherein therapeutic moieties are conjugated to one or more engineered cysteines as well as to one or more reduced interchain cysteines via a cleavable or non-cleavable linker.

Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

The present invention provides a method of treating ALK-negative/LTK-positive cancer in a subject, comprising administering to the subject a pharmaceutically-effective dose of a linear inhibitor of ALK. The invention is of particular utility in treating multiple myeloma, including proteasome inhibitor-resistant multiple myeloma.